Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31534Editorial articleПередовая статьяReview ArticleUse of anti-B-cell therapy in case of antisynthetase syndrome as the severest subtype of polymyositis/dermatomyositisПрименение анти-В-клеточной терапии при антисинтетазном синдроме как наиболее тяжелом подтипе полимиозита/дерматомиозитаAntelavaO AАнтелаваО Аantelavao@gmail.comKhelkovskaia-SergeevaA NХелковская-СергееваА НTarasovaG MТарасоваГ МNikishinaN IuНикишинаН ЮLopatinaN EЛопатинаН ЕPal'shinaS GПальшинаС ГFedinaT PФединаТ ПSazhinaE GСажинаЕ ГГБОУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава РоссииФГБУ "НИИ ревматологии им. В.А. Насоновой" РАМН, Москва15052014865VOL 86, NO5 ()ТОМ 86, №5 (2014)10911510042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31534

Antisynthetase syndrome encompassing a symptom complex with severe interstitial lung disease is the severest subtype of polymyositis and dermatomyositis. The characteristic feature of antisynthetase syndrome is the insufficient efficiency of traditional therapy with glucocorticosteroids and cytostatics, which determines the prognosis of the disease and the need for new therapeutic approaches to treating these patients.

Аннотация. Наиболее тяжелым подтипом полимиозита и дерматомиозита является антисинтетазный синдром, включающий симптомокомплекс с тяжелым интерстициальным поражением легких. Характерная особенность антисинтетазного синдрома заключается в недостаточной эффективности традиционной терапии глюкокортикостероидами и цитостатиками, что определяет прогноз болезни и обусловливает необходимость поиска новых терапевтических подходов к лечению этих пациентов.

polymyositisdermatomyositisantisynthetase syndromerituximabinterstitial lung diseaseполимиозитдерматомиозитантисинтетазный синдромритуксимабинтерстициальное поражение легкихOddis C.V., Reed A.M., Aggarwal R. et al. Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. A Randomized, Placebo-Phase Trial. Arthritis Rheum 2013; 65 (2): 314-324.Bohan A., Peter J.B., Bowman R.L., Pearson C.M. A computerassisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 255-86.Идиопатические воспалительные миопатии. Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М 2005: 192-201.Rider L.G., Miller F.W. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011; 305: 183-190.Насонов Е.Л., Антелава О.А. Идиопатические воспалительные миопатии. В кн.: Национальное руководство по ревматологии Под ред. Е.Л. Насонова, В.А. Насоновой. М: ГЭОТАР-Медиа 2008: 502-517.Plotz P.H., Dalakas M., Leff R.L. et al. Current concepts in the idiopathic inflammatory myopathies: Polymyositis, dermatomyositis and related disorders. Ann Intern Med 1989; 111 (2): 143-157.Антелава О.А., Тарасова Г.М., Сажина Е.Г. и др. Антисинтетазный синдром - наиболее тяжелый подтип полимиозита/дерматомиозита (описание случаев). Совр ревматол 2009; 4: 54-88.Katzap E., Barilla-LaBarca M.L., Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011; 13: 175-181.Антелава О.А., Балабанова Р.М., Сажина Е.Г. и др. Особенности дебюта и течения антисинтетазного синдрома как наиболее тяжелого подтипа полимиозита/дерматомиозита. Рус мед журн 2009; 17: 1443-1447.Solomon J., Swigris J.J., Brown K.K. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011; 37: 100-109.Labirua A., Lundberg I.E. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010; 22: 633-638.Бондаренко И.Б., Мухин Н.А., Насонов Е.Л. и др. Поражение легких при полимиозите и дерматомиозите. Клин мед 1998; 2: 20-24.Антелава О.А., Бондаренко И.Б., Хитров А.Н., Насонов Е.Л. Поражение дыхательной системы при полимиозите/дерматомиозите. Рус мед журн 2008; 16: 1633-1637.Bajocchi G., Piro R., Lombardini C. et al. Acute respiratory distress syndrome: an undercover antisynthetase syndrome: a case report and a review of the literature. Clin Exp Rheumatol 2012; 30 (3): 424-428.Labirua-Iturburu A., Selva-O'Callaghan A., Vincze M. et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) 2012; 91 (4): 206-211.Betteridge Z., Gunawardena H., North J. et al. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) assotiated with polymyositis and interstitial pneumonia. Rheumatology 2007; 46: 1005-1008.Chen I.J., Jan Wu Y.J., Lin C.W. et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009; 28 (6): 639-646.Santy A., Rochat Th., Schoch О.D., Hamacher J. Pulmonary fibrosis with predominant CDg lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997; 10: 2907-2912.Hervier B., Devilliers H., Stanciu R. et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012; 12 (2): 210-217.Frikha F., Saidi N., Snoussi M. et al. Antisynthetase syndrome: A report of four cases and literature review. [Article in French]. Rev Pneumol Clin 2012; 68 (6): 351-360.Stanciu R., Guiguet M., Musset L. et al. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol 2012; 39 (9): 1835-1839.Paepe B.D., Creus K.K., De Bleecker J.L. The Tumor Necrosis Factor Superfamily of Cytokines in the Inflammatory Myopathies: Potential Targets for Therapy. Clin Developmen Immunol 2012, Article ID 369432, 10 pages doi:10.1155/2012/369432.Albayda J., Christopher-Stine L. Novel approaches in the treatment of myositis and myopathies. Ther Adv Musculoskel Dis 2012; 4 (5): 369-377.Visser M. The Efficacy of Rituximab in Refractory Myositis: The Jury Is Still Out. Arthritis Rheum 2013; 65 (2): 303-306.Levine T.D. Rituximab in the treatment of dermatomyositis: anopen-label pilot study. Arthritis Rheum 2005; 52: 601-607.Антелава О.А., Насонов Е.Л. Анти-В-клеточная терапия: фокус на ритуксимаб. В кн: Ритуксимаб в лечении идиопатических воспалительных миопатий. Под ред. Е.Л. Насонова. М: ИМА-ПРЕСС 2012: 178-189.Gottenberg J.E., Guillevin L., Lambotte O. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913-920.Lambotte O., Kotb R., Maigne G. et al. Efficacy of rituximab in refractory polymyositis. J. Rheumatol 2005; 32: 1369-1370.Brulhart L., Waldburger J.M., Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 2006; 65: 974-975.Vandenbroucke E., Grutters J.C., Altenburg J. et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 2009; 29: 1499-1502.Frikha F., Rigolet A., Behin A. et al. Efficacy of rituximab in refractory and relapsing myositis with anti-Jo1 antibodies:a report of two cases. Rheumatol (Oxford) 2009; 48: 1166-1168.Sem M., Molberg O., Lund M.B. et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatol (Oxford) 2009; 48: 968-971.Ball E.M.A., Savage E.M., Pendleton A. Refractory anti-synthetase syndrome treated with rituximab. Rheumatol (Oxford) 2010; 49: 1013.Marie I., Dominique S., Janvresse A. et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 2012; 106: 571-577.Bader-Meunier B., Decaluwe H., Barnerias C. et al., for the Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunityand Rituximab registry. J Rheumatol 2011; 38: 1436-1440.Mahler E.A., Blom B., Voermans N.C. et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011; 50: 2206-2213.Rios Fernandez R. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies: a report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27: 1009-1016.Valiyil R., Casciola-Rosen L., Hong G. et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62: 1328-1334.Krystufková O., Vallerskog T., Helmers S.B. et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies [abstract]. Ann Rheum Dis 2009; 68: 836-843.Limaye V., Hissaria P., Liew C.L. et al. Efficacy of rituximab in refractory antisynthetase syndrome. Intern Med J 2012; 42: 4-7.Chiu Y.E., Co D.O. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use [published erratum appears in Pediatr Dermatol 2011; 28:627]. Pediatr Dermatol 2011; 28: 357-367.Kulkarni H.S., Aggarwal R. Successful treatment of acute respiratory failure using rituximab and cyclophosphamide as a combination immunosuppressive regimen in a ventilator-dependent patient having antisynthetase syndrome. Am J Respir Crit Care Med 2011; 183; A5661.Gazeley D.J. Cronin M.E. Diagnosis and treatment of the idiopathic inflammatory myopathies Therapeutic Advances in Musculoskeletal Disease 2011; 3: 315-324.